Objective: To determine whether dietary modi®cation rather than use of supplements can raise indices of vitamin E status to potentially cardioprotective levels. Design: Eight week randomised controlled trial with parallel treatments to compare increased use of vitamin Erich foods, supplementation with 200 IU of vitamin E, and a placebo. Setting: Dunedin, New Zealand. Subjects: Ninety subjects were recruited, of whom 82 non-smoking, free-living individuals aged 22 ± 72 y with plasma cholesterol`7.5 mmolal completed the trial. Main outcome measures: Dietary intakes, plasma alpha tocopherol, plasma alpha tocopherolacholesterol ratio and lipoprotein cholesterol. Results: Consumption of an additional 12 mg of vitamin E (alpha tocopherol equivalents) from dietary sources was primarily achieved through the replacement of saturated fat-rich foods with unsaturated fats rich in vitamin E, nuts and vegetables. This resulted in a 3.4 mmolal increase in plasma alpha tocopherol at week 6 (95% CI 1.6 ± 5.3), and 0.9 mmolammol in plasma alpha tocopherolacholesterol at weeks 4 and 6 (95% CI 0.3 ± 1.4 and 0.4 ± 1.4, respectively) when compared with the placebo group. In the supplement group, plasma alpha tocopherol and plasma alpha tocopherolacholesterol were signi®cantly increased within 2 weeks and remained so throughout the 8 week intervention. Conclusion: Increasing dietary vitamin E intake can increase plasma alpha tocopherol levels, although factors other than dietary intake are also important determinants. The extent of dietary modi®cation required to achieve potentially cardioprotective levels of plasma alpha tocopherol is dif®cult in practice.
Introduction
A considerable body of evidence suggests that vitamin E helps to protect against coronary heart disease. Prospective epidemiological studies have demonstrated reduced risk of subsequent coronary heart disease amongst those with the highest intakes of vitamin E (Knekt et al, 1994; Kushi et al, 1996; Rimm et al, 1993; Stampfer et al, 1993) . There are plausible biological mechanisms to support the epidemiological association (Diaz et al, 1997) . In experimental studies, enriching low density lipoprotein (LDL) with vitamin E reduces the oxidisability of this lipoprotein fraction (Esterbauer et al, 1997; Jialal & Grundy, 1992) , which in turn is believed to reduce its atherogenic potential (Regnstrom et al, 1996) . However, despite this body of evidence suggesting a bene®cial effect of vitamin E, it has not yet been established with certainty whether vitamin E-rich foods or supplemental vitamin E confer particular bene®ts. The results of some epidemiological studies have suggested that vitamin E intakes as supplements might be particularly bene®cial (Rimm et al, 1993; Stampfer et al, 1993) , others that dietary sources are preferable (Kushi et al, 1996) . Clinical trials of supplemental vitamin E have also generated con¯icting results. The CHAOS trial suggested a signi®cant reduction of clinical cardiovascular events, although not of cardiovascular or total mortality (Stephens et al, 1996) . Three other randomised controlled trials have found no signi®cant difference in cardiovascular endpoints between supplemented and placebo groups (Anonymous, 1994 (Anonymous, , 1999 Yusuf et al, 2000) . There is also no certainty regarding the optimal cardioprotective amounts of vitamin E, whether from dietary sources or from supplements. As a contribution to this debate we describe here a study aimed to determine the extent to which increasing intakes of vitamin E from food sources beyond the usual dietary intakes can elevate plasma levels and in particular whether it is possible by this means to achieve levels which are associated with reduced cardiovascular risk.
Methods
The study was approved by the University of Otago Human Ethics Committee, and informed consent was obtained from all participants.
The 8 week study involved a randomised, controlled design with parallel treatments. There were three treatment groups: placebo, supplement and dietary intervention. The placebo and supplement groups were treated in a double-blind manner, with the participants taking either a placebo capsule, or a 200 International Units (IU) RRR-alpha tocopherol capsule daily for the 8 weeks, whilst continuing with their usual diets. Participants were selected from a group of volunteers recruited by means of advertisements in local newspapers and on local radio. All were over 18 y and met the following inclusion criteria: total plasma cholesterol 7.5 mmolal, plasma triglyceride`3.0 mmolal, non-smokers, not taking any vitamin E-containing supplements or medication known to affect lipid metabolism, and with no pre-existing serious medical condition.
Ninety healthy adult volunteers from Dunedin, New Zealand entered the trial. During a 1 week run-in period before randomisation all participants consumed their usual diet and completed a 4 day estimated diet record over 1 weekend day and 3 week days. Standardised cups and spoons were provided and guidance given regarding the recording of the nature and amounts of foods and beverages consumed (Gibson, 1990) . Four-day diet records were also completed during weeks 4 and 8 of the intervention. Nutrient intakes were calculated using data from the 1997 New Zealand Food Composition Database.
Participants were allocated using random numbers so that 10 were allocated to a vitamin E supplement group (200 IUaday), 40 to a placebo (control) group and 40 to a dietary intervention group. Eighty two participants completed the trial; ®ve withdrew due to illness, family bereavement or overseas travel and three were lost to follow-up during the trial.
A 20 ml fasting venous blood sample was collected at the time of randomisation (baseline) and at 2, 4, 6 and 8 weeks of the intervention. The blood samples were collected by venipuncture from an antecubital vein after a 10 ± 12 h overnight fast. Blood samples were collected into vacutainer tubes containing disodium-EDTA. Upon collection tubes were immediately placed on ice in the dark.
Plasma was separated within 2 h of collection by centrifugation of whole blood at 2000 g for 10 min at 4 C. Aliquots for plasma cholesterol, triglyceride and alpha tocopherol analysis were stored at À80 C. Participants in the diet group were asked to eat a diet in which the majority of fat came from foods rich in vitamin E. The goal was for participants in the diet group to reach a vitamin E intake of 30 ± 40 mgaday. Foods with a high alpha-tocopherol content were chosen because the bioavailability of this form of vitamin E is highest. Participants were provided with 460 g of ground hazelnuts (25 mg vitamin Ea100 g), 500 g of a canola-based margarine (15 mg vitamin Ea100 g), and 100 ml of wheatgerm oil (127 mg vitamin Ea100 g) every fortnight and asked to consume roughly 70 gaday 30 gaday and 5 mladay of the food products, respectively. Eaten in these amount the foods provided 28 mgaday. Participants were also encouraged to increase other vitamin E-rich foods such as avocado and pumpkin. They were asked to keep the amount of other fats (added fats, foods naturally high in fat) in the diet to a minimum, and to use only the margarine, oil and nuts supplied in an attempt to prevent a large increase in the polyunsaturated fat intake. The diet of each individual was tailored according to individual taste and in order to achieve a calculated total fat intake of 30% total energy. At the outset of the intervention detailed dietary instructions, recipes and suggestions for baking and cooking with the foods were given to participants and at fortnightly intervals personal dietary counselling was provided by a research dietitian.
Vitamin E supplements were provided by Thompson Nutrition Ltd. Each capsule contained 200 IU RRR-alpha tocopherol. Product speci®cation was veri®ed independently. Healtheries lecithin capsules (200 mg) encapsulated in soya oil and free from vitamin E were used for the placebo group. The placebo and supplement groups were instructed to continue their usual diets.
Alpha tocopherol in plasma was determined using the high pressure liquid choromatography (HPLC) method of Thurnham et al (1988) . The HPLC system consisted of a Shimadzu SCL-6A system controller, two LC-6A liquid chromatographs, an SPD-6AV detector and SGE LS-3200 autosampler. The column (Phenomenex prodigy C18 5 ODS 3 100A 150Â4.6 mm) was ®tted with a 30Â4.6 mm guard column and kept at a constant 30.2 C using a column heater. Mobile phase (acetonitrileamethanolachloroform 47a47a6 vav) was pumped through the column at a¯ow rate of 2.0 mlamin. Alpha tocopherol was monitored at 292 nm between 3 and 9 min, and tocopherol acetate (internal standard) was detected at 284 nm during the 15 min run.
Precision was determined by the analysis of pooled plasma measured over a 13 run period between June and August 1998. Average pooled plasma alpha tocopherol was 23.11 mmolal, and overall coef®cient of variation 6.9% (n 51). Analytical accuracy and reliability were veri®ed by analysis of lyophilised quality control sera from the US National Bureau of Standards.
Vitamin E-rich diet vs supplemental JK McGavin et al
Plasma total cholesterol and triglyceride (TG) concentrations were measured by enzymatic methods using kits and calibrators from Boehringer Mannheim and Roche Diagnostics on a Roche Cobas Fara II auto-analyser. Plasma high density lipoprotein (HDL) cholesterol was measured in the supernatant after precipitation of apoprotein B containing lipoproteins with phosphotungstatea magnesium chloride solution (Assmann et al, 1983) . Plasma low density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation (Friedewald et al, 1972) . Calibration and quality control was maintained by participation in the Royal Australasian College of Pathologists quality assurance programme. The coef®cients of variation for measurements during the study period were 0.9% for plasma total cholesterol, 2.7% for plasma TG and 5.2% for plasma HDL cholesterol. All statistical analyses were performed using SPSS 6.1 for Macintosh (SPSS Inc).
Multiple regression analysis was used to detect differences between treatment groups using dummy group variables. Adjustments were made for baseline values. Plasma alpha tocopherol and plasma alpha tocopherolacholesterol values were normally distributed, therefore actual values were used in the regression model. Dietary vitamin E only. *Signi®cant difference from the placebo group.
Pearson correlation matrices (two-tailed) were calculated to determine the association between dietary and plasma alpha tocopherol measurements. The relationships between changes in these variables and changes in plasma alpha tocopherol in the two intervention groups (diet and supplement) were examined using the changes which occurred between weeks 0 and 8.
Results
Baseline clinical and laboratory characteristics of the three groups are shown in Table 1 . The mean age was 48.0 y (range 22 ± 72) and mean body mass index (BMI) 25.9 kgam 2 (range 18.2 ± 40.7). BMI remained unchanged throughout the study period. Mean plasma alpha tocopherol levels of the entire group was 26.9 mmolal (range 16.7 ± 45.5) and plasma alpha tocopherolacholesterol 5.3 mmolammol (range 3.1 ± 9.3). Mean plasma total cholesterolesterol at baseline was similar in all groups, but plasma HDL was lower and plasma TG higher in the dietary group as compared with the placebo group.
The reported energy and nutrient composition of the diets consumed by participants in the supplement and placebo groups were virtually identical throughout the 8 week study period (Table 2) . Vitamin E intake at week 8 was higher by 12 mgaday in the diet group than in the placebo group. Participants in the diet group ate less saturated fat and more total, monounsaturated and polyunsaturated fat than their counterparts in the placebo group, although the magnitude of the differences was relatively small. Participants in the diet group reported eating an average of 4 ml of wheatgerm oil, 12 g of canola margarine, and 24 g of hazelnuts per day, contributing 5, 2 and 6 mg of vitamin E, respectively.
Seven participants in the diet group were able to reach the target of 30 mg vitamin E per day; the remaining 28 averaged 18 mgaday. Nineteen volunteers reached at least 20 mgaday, consuming on average 29 mgaday.
Plasma levels of vitamin E are presented in Table 3 . At baseline there were no signi®cant differences between the groups. In the dietary group plasma alpha tocopherol was higher than in the placebo group at weeks 2, 4, 6 and 8 but reached statistical signi®cance only at week 6. Signi®cant increases in alpha tocopherol expressed in relation to total cholesterol (plasma alpha tocopherolacholesterol) were seen in the dietary group at weeks 4 and 6. Levels in the placebo group remained unchanged during the course of the study. 
Vitamin E-rich diet vs supplemental JK McGavin et al
Plasma total cholesterol and plasma alpha tocopherol concentrations at baseline were signi®cantly correlated (Figure 1 ). At baseline dietary vitamin E intake was not correlated with plasma alpha tocopherol concentrations (Figure 2) . Analysis of the diet and placebo groups alone (Figure 3) showed a signi®cant correlation between change in dietary vitamin E and change in plasma alpha tocopherol (r 0.28, P 0.027). Change in dietary vitamin E was not correlated with change in plasma alpha tocopherolacholesterol (r 0.19, P 0.135).
The mean (s.d.) BMI and levels of plasma lipids are shown in Table 4 . BMI remained unchanged throughout the study period. Levels of plasma high density lipoprotein were lower and plasma triglyceride higher in the dietary group compared with the placebo group at all blood sampling periods. Even after adjustment for differences at baseline, plasma high density lipoprotein was lower in the diet group compared with the placebo group. Plasma triglyceride was not signi®cantly different between the groups at week 8 after adjustment for initial differences Vitamin E-rich diet vs supplemental JK McGavin et al between the groups. There were no other changes in plasma lipids in any of the groups throughout the study period.
Discussion
The major purpose of this study was to determine the extent to which it is possible to increase plasma levels of alpha tocopherol by dietary means and in particular whether it is possible to achieve cardioprotective levels by dietary modi®cation rather than by using supplements. Cross-sectional epidemiological studies (Bellizzi et al, 1994) and several experimental investigations have led to the suggestion that plasma alpha tocopherol levels of 27.5 mmolal or greater may be necessary to reduce cardiovascular risk (Gey et al, 1993) and that this is likely to be achieved by average daily dietary intakes of vitamin E of 15 ± 30 mg. Longitudinal studies which have measured plasma levels have been equivocal, probably because measurements have been made after prolonged periods of sample storage (Kok et al, 1987; Salonen et al, 1985) . Typically in Western societies vitamin E intakes are around 10 mg per day. On average our participants allocated to the diet group were able to approximately double their average reported intake of vitamin E from 10 to 22 mgaday, but fewer than one-®fth achieved the target of 30 mg. Despite advice to obtain a larger proportion of additional vitamin E from nuts and vegetables rather than oils, the contribution of unsaturated oils (wheatgerm oil and margarine) rich in vitamin E was larger than desired. Thus, the vitamin EXPUFA ratio was slightly higher in the diet than in the placebo group.
The small increases in plasma alpha tocopherol observed throughout the dietary period achieved statistical signi®-cance only at week 6, and the plasma alpha tocopherola cholesterol ratio at weeks 4 and 6. The con®dence intervals surrounding the adjusted differences between dietary and placebo groups suggests that a study with a larger number of subjects might have achieved statistically signi®cant differences but the minimal increase in plasma alpha tocopherol was nevertheless both surprising and disappointing. It is conceivable that the relatively high baseline levels of the participants may have reduced the plasma alpha tocopherol-raising potential of the dietary intervention (Hense et al, 1993) , although we did not ®nd a greater increase in plasma alpha tocopherol in participants who at baseline had plasma alpha tocopherol levels in the lowest quartile of the sample population (results not shown). Furthermore, the increased PUFA intake may have increased the requirement for vitamin E (Muggli, 1994; Weber et al, 1997) . However the correlation between reported change in vitamin E on the one hand and change in plasma alpha tocopherol on the other con®rms the ®nding from the diet records that inability to comply with the dietary advice (fewer than 20% achieved the target intake), despite intensive dietary instruction, is an important determinant of failure to achieve higher plasma alpha tocopherol levels. We are unaware of comparable data regarding the plasma alpha tocopherol-raising effect of increasing dietary vitamin E, but the fact that 80% of self-selected highly motivated individuals were unable to meet the target suggests that in practice it will be extremely dif®cult to raise plasma alpha tocopherol to over 30 mmolal without the use of supplements. 200 IU RRR-alpha tocopherol raised levels to over 40 mmolal.
Despite the apparent tight homeostatic mechanisms governing vitamin E levels, dietary intakes must determine plasma levels as there is no endogenous production of vitamin E (Traber, 1994) . Our data con®rm the complexity of determinants of the bioavailability of vitamin E. It is conceivable that other nutrients or biologically active substances in food may in¯uence bioavailability, but it is also possible that substantial increases in the amounts of dietary vitamin E to levels which are only achievable by the use of supplements are essential for a substantial increase in plasma levels. Prior to the dietary intervention we found a strong correlation between plasma cholesterol and plasma alpha tocopherol, a ®nding demonstrated by several other groups (Horwitt et al, 1972; Lehmann et al, 1988; Vatassery et al, 1983) . However, no correlation is apparent between dietary intake and plasma alpha tocopherol at baseline, especially when supplement users are eliminated from the overall group. These ®ndings are compatible with several sets of data (Booth et al, 1997; Kardinaal et al, 1995) but not others (Ascherio et al, 1992; Jacques et al, 1993) . Failure to demonstrate a convincing association between dietary and plasma vitamin E in cross-sectional studies, especially when supplement users are excluded, is probably a consequence of the relatively narrow range of intakes as well as the dif®culty involved in assessing dietary intake. Nevertheless, the signi®cant correlation between reported change in dietary vitamin E and change in plasma alpha tocopherol levels, despite the dif®culty in assessing dietary intake, con®rms that dietary intake of vitamin E from foods has some in¯uence on plasma levels. Dose ± response and time course studies suggest that changes in plasma alpha tocopherol with doses of supplemental vitamin E are seen within 10 ± 24 h (Dimitrov et al, 1991) . Our data suggests that the maximum change occurs after 4 weeks on a supplement or after 6 weeks when altering dietary intakes. A wide variation in response to ingested vitamin E has been reported previously and the existence of responders and nonresponders has been suggested (Dimitrov et al, 1991; Tangney et al, 1987) .
The debate regarding the pros and cons of increasing vitamin E will no doubt continue. Despite strong circumstantial evidence for bene®t from epidemiological and experimental studies the results of clinical trials involving supplemental vitamin E remain inconclusive. The Cambridge secondary prevention trial (CHAOS) suggested bene®t in terms of reducing recurring clinical events but not of cardiovascular or total mortality (Stephens et al, 1996) . The recent large Italian trial (Anonymous, 1999) suggested possible bene®t, but the results did not achieve conventional statistical signi®cance. The HOPE study Vitamin E-rich diet vs supplemental JK McGavin et al found similar rates of clinical events in the supplemented and placebo groups (Yusuf et al, 2000) . The Alpha Tocopherol Beta Carotene Trial also found that vitamin E did not reduce coronary events (Rapola et al, 1997) . Our study contributes by demonstrating an association between increase in dietary vitamin E and change in plasma levels and the potential for raising levels without adversely affecting the vitamin EXPUFA ratio. However, given the dif®culty in achieving target dietary intakes and the relatively small effect in exceptionally well-motivated volunteers who were given intensive dietary instruction and supplied with appropriate foods at no cost, it seems most unlikely that a change in diet will achieve more than very modest elevations in plasma levels of individuals. Supplemental vitamin E appears to be the only means of appreciably raising plasma alpha tocopherol levels; however, the overall clinical bene®t of this practice remains to be proven.
